The role of type I interferons in intestinal infection, homeostasis, and inflammation

Immunological Reviews

Volumn 260, Issue 1, 2014, Pages 145-167

  Cho, Hyeseon ^a   Kelsall, Brian L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Enteric microbial infection; Intestinal inflammation; Type I interferons

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN P 15095; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 6; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3;

ACUTE DISEASE; ASYMPTOMATIC INFECTION; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; CELIAC DISEASE; CHRONIC DISEASE; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENTERITIS; GASTROENTERITIS; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INFLUENZA; INTESTINE INFECTION; LACTOBACILLUS; LISTERIA MONOCYTOGENES; LYMPHOCYTE DIFFERENTIATION; MENINGITIS; MULTICENTER STUDY (TOPIC); NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOVIRUS; REOVIRUS INFECTION; REVIEW; ROTAVIRUS; ROTAVIRUS INFECTION; SALMONELLA TYPHIMURIUM; SEPTIC ABORTION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; VIRUS CAPSID; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; INTESTINE; METABOLISM; MICROBIOLOGY; MOUSE; PATHOLOGY; VIROLOGY;

ANIMALS; BACTERIAL INFECTIONS; DISEASE MODELS, ANIMAL; HOMEOSTASIS; HUMANS; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERFERON TYPE I; INTESTINES; MICE; VIRUS DISEASES;

EID: 84902584152     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12195     Document Type: Review

References (251)

1. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32.
2. Hertzog PJ, Williams BR. Fine tuning type I interferon responses. Cytokine Growth Factor Rev 2013;24:217-225.
3. Young HA, Bream JH. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol 2007;316:97-117.
4. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009;284:20869-20875.
5. Kotenko SV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
6. Sheppard P, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-68.
7. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011;23:583-590.
8. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017.
9. Nguyen KB, et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 2002;297:2063-2066.
10. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125-135.
11. Kole A, et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cell-mediated colitis. J Immunol 2013;191:2771-2779.
12. Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012;36:166-174.
13. Monroe KM, McWhirter SM, Vance RE. Induction of type I interferons by bacteria. Cell Microbiol 2010;12:881-890.
14. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207:2053-2063.
15. Eitel J, Suttorp N, Opitz B. Innate immune recognition and inflammasome activation in listeria monocytogenes infection. Front Microbiol 2010;1:149.
16. Malireddi RK, Kanneganti TD. Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection. Front Cell Infect Microbiol 2013;3:77.
17. Mayer-Barber KD, et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011;35:1023-1034.
18. Guarda G, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011;34:213-223.
19. MacMicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 2012;12:367-382.
20. Wilson EB, Brooks DG. Decoding the complexity of type I interferon to treat persistent viral infections. Trends Microbiol 2013;21:634-640.
21. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14:36-49.
22. Swiecki M, Colonna M. Type I interferons: diversity of sources, production pathways and effects on immune responses. Curr Opin Virol 2011;1:463-475.
23. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
24. Wilkins C, Gale M, Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010;22:41-47.
25. Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol 2012;86:2900-2910.
26. Lupfer C, Kanneganti TD. The expanding role of NLRs in antiviral immunity. Immunol Rev 2013;255:13-24.
27. Mattei F, Schiavoni G, Tough DF. Regulation of immune cell homeostasis by type I interferons. Cytokine Growth Factor Rev 2010;21:227-236.
28. Tate JE, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:136-141.
29. Ouattara LA, et al. Novel human reovirus isolated from children with acute necrotizing encephalopathy. Emerg Infect Dis 2011;17:1436-1444.
30. Fleeton MN, Contractor N, Leon F, Wetzel JD, Dermody TS, Kelsall BL. Peyer's patch dendritic cells process viral antigen from apoptotic epithelial cells in the intestine of reovirus-infected mice. J Exp Med 2004;200:235-245.
31. Forrest JC, Dermody TS. Reovirus receptors and pathogenesis. J Virol 2003;77:9109-9115.
32. Glass RI, Parashar UD, Estes MK. Norovirus gastroenteritis. N Engl J Med 2009;361:1776-1785.
33. Zhang S, et al. Symptomatic and asymptomatic infections of rotavirus, norovirus, and adenovirus among hospitalized children in Xi'an, China. J Med Virol 2011;83:1476-1484.
34. Schwartz S, et al. Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation. Blood 2011;117:5850-5856.
35. Roos-Weil D, et al. Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea. Transplantation 2011;92:61-69.
36. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005;15:29-56.
37. Blutt SE, Conner ME. The gastrointestinal frontier: IgA and viruses. Front Immunol 2013;4:402.
38. Blutt SE, et al. Rotavirus antigenemia in children is associated with viremia. PLoS Med 2007;4:e121.
39. Lopatin U, Blutt SE, Conner ME, Kelsall BL. Lymphotoxin alpha-deficient mice clear persistent rotavirus infection after local generation of mucosal IgA. J Virol 2013;87:524-530.
40. Kuss SK, et al. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 2011;334:249-252.
41. Pfeiffer JK, Sonnenburg JL. The intestinal microbiota and viral susceptibility. Front Microbiol 2011;2:92.
42. Arnold MM, Sen A, Greenberg HB, Patton JT. The battle between rotavirus and its host for control of the interferon signaling pathway. PLoS Pathog 2013;9:e1003064.
43. Davidson GP, Barnes GL. Structural and functional abnormalities of the small intestine in infants and young children with rotavirus enteritis. Acta Paediatr Scand 1979;68:181-186.
44. Frias AH, et al. Intestinal epithelia activate anti-viral signaling via intracellular sensing of rotavirus structural components. Mucosal Immunol 2010;3:622-632.
45. Broquet AH, Hirata Y, McAllister CS, Kagnoff MF. RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium. J Immunol 2011;186:1618-1626.
46. Pott J, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA 2011;108:7944-7949.
47. Sen A, Pruijssers AJ, Dermody TS, Garcia-Sastre A, Greenberg HB. The early interferon response to rotavirus is regulated by PKR and depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3. J Virol 2011;85:3717-3732.
48. Douagi I, et al. Role of interferon regulatory factor 3 in type I interferon responses in rotavirus-infected dendritic cells and fibroblasts. J Virol 2007;81:2758-2768.
49. Uzri D, Greenberg HB. Characterization of rotavirus RNAs that activate innate immune signaling through the RIG-I-like receptors. PLoS ONE 2013;8:e69825.
50. Deal EM, Jaimes MC, Crawford SE, Estes MK, Greenberg HB. Rotavirus structural proteins and dsRNA are required for the human primary plasmacytoid dendritic cell IFNalpha response. PLoS Pathog 2010;6:e1000931.
51. Pott J, et al. Age-dependent TLR3 expression of the intestinal epithelium contributes to rotavirus susceptibility. PLoS Pathog 2012;8:e1002670.
52. Sato A, et al. Rotavirus double-stranded RNA induces apoptosis and diminishes wound repair in rat intestinal epithelial cells. J Gastroenterol Hepatol 2006;21:521-530.
53. Zhou R, Wei H, Sun R, Tian Z. Recognition of double-stranded RNA by TLR3 induces severe small intestinal injury in mice. J Immunol 2007;178:4548-4556.
54. McAllister CS, et al. TLR3, TRIF, and caspase 8 determine double-stranded RNA-induced epithelial cell death and survival in vivo. J Immunol 2013;190:418-427.
55. Lecce JG, Cummins JM, Richards AB. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. Mol Biother 1990;2:211-216.
56. Schwers A, Vanden Broecke C, Maenhoudt M, Beduin JM, Werenne J, Pastoret PP. Experimental rotavirus diarrhoea in colostrum-deprived newborn calves: assay of treatment by administration of bacterially produced human interferon (Hu-IFN alpha 2). Ann Vet Res 1985;16:213-218.
57. Angel J, Franco MA, Greenberg HB, Bass D. Lack of a role for type I and type II interferons in the resolution of rotavirus-induced diarrhea and infection in mice. J Interferon Cytokine Res 1999;19:655-659.
58. Broome RL, Vo PT, Ward RL, Clark HF, Greenberg HB. Murine rotavirus genes encoding outer capsid proteins VP4 and VP7 are not major determinants of host range restriction and virulence. J Virol 1993;67:2448-2455.
59. Feng N, et al. Role of interferon in homologous and heterologous rotavirus infection in the intestines and extraintestinal organs of suckling mice. J Virol 2008;82:7578-7590.
60. Sen A, et al. Innate immune response to homologous rotavirus infection in the small intestinal villous epithelium at single-cell resolution. Proc Natl Acad Sci USA 2012;109:20667-20672.
61. Deal EM, Lahl K, Narvaez CF, Butcher EC, Greenberg HB. Plasmacytoid dendritic cells promote rotavirus-induced human and murine B cell responses. J Clin Invest 2013;123:2464-2474.
62. Siegal FP, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
63. Asselin-Paturel C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001;2:1144-1150.
64. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000;1:305-310.
65. Cella M, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999;5:919-923.
66. Cerutti A, Qiao X, He B. Plasmacytoid dendritic cells and the regulation of immunoglobulin heavy chain class switching. Immunol Cell Biol 2005;83:554-562.
67. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003;19:225-234.
68. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-470.
69. Varani S, et al. Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol 2007;179:7767-7776.
70. Holm GH, et al. Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3. J Biol Chem 2007;282:21953-21961.
71. Saito T, et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci USA 2007;104:582-587.
72. Kato H, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 2008;205:1601-1610.
73. Loo YM, et al. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 2008;82:335-345.
74. Satoh T, et al. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc Natl Acad Sci USA 2010;107:1512-1517.
75. Zhang Z, et al. DDX1, DDX21, and DHX36 helicases form a complex with the adaptor molecule TRIF to sense dsRNA in dendritic cells. Immunity 2011;34:866-878.
76. Liu Y, et al. The interaction between the helicase DHX33 and IPS-1 as a novel pathway to sense double-stranded RNA and RNA viruses in myeloid dendritic cells. Cell Mol Immunol 2014;11:49-57.
77. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell RA, Oldstone MB. Does Toll-like receptor 3 play a biological role in virus infections? Virology 2004;322:231-238.
78. Wolf JL, et al. Intestinal M cells: a pathway for entry of reovirus into the host. Science 1981;212:471-472.
79. Bodkin DK, Nibert ML, Fields BN. Proteolytic digestion of reovirus in the intestinal lumens of neonatal mice. J Virol 1989;63:4676-4681.
80. Kauffman RS, Wolf JL, Finberg R, Trier JS, Fields BN. The sigma 1 protein determines the extent of spread of reovirus from the gastrointestinal tract of mice. Virology 1983;124:403-410.
81. Fan JY, Boyce CS, Cuff CF. T-Helper 1 and T-helper 2 cytokine responses in gut-associated lymphoid tissue following enteric reovirus infection. Cell Immunol 1998;188:55-63.
82. Major AS, Cuff CF. Enhanced mucosal and systemic immune responses to intestinal reovirus infection in beta2-microglobulin-deficient mice. J Virol 1997;71:5782-5789.
83. London SD, Rubin DH, Cebra JJ. Gut mucosal immunization with reovirus serotype 1/L stimulates virus-specific cytotoxic T cell precursors as well as IgA memory cells in Peyer's patches. J Exp Med 1987;165:830-847.
84. Johansson C, Wetzel JD, He J, Mikacenic C, Dermody TS, Kelsall BL. Type I interferons produced by hematopoietic cells protect mice against lethal infection by mammalian reovirus. J Exp Med 2007;204:1349-1358.
85. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 2006;346:312-323.
86. Bull RA, Eden JS, Rawlinson WD, White PA. Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog 2010;6:e1000831.
87. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002;185:1335-1337.
88. Tan M, Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog 2010;6:e1000983.
89. Strong DW, Thackray LB, Smith TJ, Virgin HW. Protruding domain of capsid protein is necessary and sufficient to determine murine norovirus replication and pathogenesis in vivo. J Virol 2012;86:2950-2958.
90. McCartney SA, Thackray LB, Gitlin L, Gilfillan S, Virgin HW, Colonna M. MDA-5 recognition of a murine norovirus. PLoS Pathog 2008;4:e1000108.
91. Jung K, et al. The effects of simvastatin or interferon-alpha on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. PLoS ONE 2012;7:e41619.
92. Thackray LB, et al. Critical role for interferon regulatory factor 3 (IRF-3) and IRF-7 in type I interferon-mediated control of murine norovirus replication. J Virol 2012;86:13515-13523.
93. Lazear HM, et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 2013;9:e1003118.
94. Karst SM, Wobus CE, Lay M, Davidson J, Virgin H. STAT1-dependent innate immunity to a Norwalk-like virus. Science 2003;299:1575-1578.
95. Wobus CE, et al. Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol 2004;2:e432.
96. Changotra H, et al. Type I and type II interferons inhibit the translation of murine norovirus proteins. J Virol 2009;83:5683-5692.
97. Mumphrey SM, et al. Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J Virol 2007;81:3251-3263.
98. Hubbard VM, Cadwell K. Viruses, autophagy genes, and Crohn's disease. Viruses 2011;3:1281-1311.
99. Cadwell K, et al. A key role for autophagy and the autophagy gene Atg16 l1 in mouse and human intestinal Paneth cells. Nature 2008;456:259-263.
100. Cadwell K, Patel KK, Komatsu M, Virgin H, Stappenbeck TS. A common role for Atg16L1, Atg5 and Atg7 in small intestinal Paneth cells and Crohn disease. Autophagy 2009;5:250-252.
101. Cadwell K, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 2010;141:1135-1145.
102. Kim YG, et al. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe 2011;9:496-507.
103. Sherry B. Rotavirus and reovirus modulation of the interferon response. J Interferon Cytokine Res 2009;29:559-567.
104. Hua J, Chen X, Patton JT. Deletion mapping of the rotavirus metalloprotein NS53 (NSP1): the conserved cysteine-rich region is essential for virus-specific RNA binding. J Virol 1994;68:3990-4000.
105. Barro M, Patton JT. Rotavirus NSP1 inhibits expression of type I interferon by antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. J Virol 2007;81:4473-4481.
106. Arnold MM, Patton JT. Diversity of interferon antagonist activities mediated by NSP1 proteins of different rotavirus strains. J Virol 2011;85:1970-1979.
107. Arnold MM, Barro M, Patton JT. Rotavirus NSP1 mediates degradation of interferon regulatory factors through targeting of the dimerization domain. J Virol 2013;87:9813-9821.
108. Graff JW, Ettayebi K, Hardy ME. Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism. PLoS Pathog 2009;5:e1000280.
109. Silvestri LS, Taraporewala ZF, Patton JT. Rotavirus replication: plus-sense templates for double-stranded RNA synthesis are made in viroplasms. J Virol 2004;78:7763-7774.
110. Holloway G, Truong TT, Coulson BS. Rotavirus antagonizes cellular antiviral responses by inhibiting the nuclear accumulation of STAT1, STAT2, and NF-kappaB. J Virol 2009;83:4942-4951.
111. Sen A, Rott L, Phan N, Mukherjee G, Greenberg HB. Rotavirus NSP1 protein inhibits interferon-mediated STAT1 activation. J Virol 2014;88:41-53.
112. Zhang R, et al. Homologous 2′, 5′-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity. Proc Natl Acad Sci USA 2013;110:13114-13119.
113. Zurney J, Kobayashi T, Holm GH, Dermody TS, Sherry B. Reovirus mu2 protein inhibits interferon signaling through a novel mechanism involving nuclear accumulation of interferon regulatory factor 9. J Virol 2009;83:2178-2187.
114. Yue Z, Shatkin AJ. Double-stranded RNA-dependent protein kinase (PKR) is regulated by reovirus structural proteins. Virology 1997;234:364-371.
115. Shmulevitz M, Pan LZ, Garant K, Pan D, Lee PW. Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res 2010;70:4912-4921.
116. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PW. Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002;62:1696-1701.
117. McFadden N, et al. Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4. PLoS Pathog 2011;7:e1002413.
118. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. Nat Immunol 2009;10:1065-1072.
119. Takaoka A, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448:501-505.
120. Wang Z, et al. Regulation of innate immune responses by DAI (DLM-1/ZBP1) and other DNA-sensing molecules. Proc Natl Acad Sci USA 2008;105:5477-5482.
121. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008;455:674-678.
122. Zhong B, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 2008;29:538-550.
123. Sun W, et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc Natl Acad Sci USA 2009;106:8653-8658.
124. Park JH, et al. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J Immunol 2007;178:2380-2386.
125. Leber JH, Crimmins GT, Raghavan S, Meyer-Morse NP, Cox JS, Portnoy DA. Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen. PLoS Pathog 2008;4:e6.
126. O'Riordan M, Yi CH, Gonzales R, Lee KD, Portnoy DA. Innate recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc Natl Acad Sci USA 2002;99:13861-13866.
127. Reimer T, Schweizer M, Jungi TW. Type I IFN induction in response to Listeria monocytogenes in human macrophages: evidence for a differential activation of IFN regulatory factor 3 (IRF3). J Immunol 2007;179:1166-1177.
128. Sing A, et al. Bacterial induction of beta interferon in mice is a function of the lipopolysaccharide component. Infect Immun 2000;68:1600-1607.
129. Pamer EG. Immune responses to Listeria monocytogenes. Nat Rev Immunol 2004;4:812-823.
130. Guiney DG. The role of host cell death in Salmonella infections. Curr Top Microbiol Immunol 2005;289:131-150.
131. Gaillard JL, Berche P, Frehel C, Gouin E, Cossart P. Entry of L. monocytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci. Cell 1991;65:1127-1141.
132. Pentecost M, Otto G, Theriot JA, Amieva MR. Listeria monocytogenes invades the epithelial junctions at sites of cell extrusion. PLoS Pathog 2006;2:e3.
133. Nikitas G, Deschamps C, Disson O, Niault T, Cossart P, Lecuit M. Transcytosis of Listeria monocytogenes across the intestinal barrier upon specific targeting of goblet cell accessible E-cadherin. J Exp Med 2011;208:2263-2277.
134. Kernbauer E, Maier V, Rauch I, Muller M, Decker T. Route of infection determines the impact of type I interferons on innate immunity to Listeria monocytogenes. PLoS ONE 2013;8:e65007.
135. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature 2009;461:788-792.
136. Abdullah Z, et al. RIG-I detects infection with live Listeria by sensing secreted bacterial nucleic acids. EMBO J 2012;31:4153-4164.
137. Hagmann CA, et al. RIG-I detects triphosphorylated RNA of Listeria monocytogenes during infection in non-immune cells. PLoS ONE 2013;8:e62872.
138. Woodward JJ, Iavarone AT, Portnoy DA. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010;328:1703-1705.
139. Parvatiyar K, et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol 2012;13:1155-1161.
140. Stockinger S, et al. IFN regulatory factor 3-dependent induction of type I IFNs by intracellular bacteria is mediated by a TLR- and Nod2-independent mechanism. J Immunol 2004;173:7416-7425.
141. O'Connell RM, Vaidya SA, Perry AK, Saha SK, Dempsey PW, Cheng G. Immune activation of type I IFNs by Listeria monocytogenes occurs independently of TLR4, TLR2, and receptor interacting protein 2 but involves TNFR-associated NF kappa B kinase-binding kinase 1. J Immunol 2005;174:1602-1607.
142. Stockinger S, Decker T. Novel functions of type I interferons revealed by infection studies with Listeria monocytogenes. Immunobiology 2008;213:889-897.
143. Aubry C, et al. Both TLR2 and TRIF contribute to interferon-beta production during Listeria infection. PLoS ONE 2012;7:e33299.
144. Auerbuch V, Brockstedt DG, Meyer-Morse N, O'Riordan M, Portnoy DA. Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med 2004;200:527-533.
145. Carrero JA, Calderon B, Unanue ER. Type I interferon sensitizes lymphocytes to apoptosis and reduces resistance to Listeria infection. J Exp Med 2004;200:535-540.
146. O'Connell RM, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med 2004;200:437-445.
147. Carrero JA, Calderon B, Unanue ER. Lymphocytes are detrimental during the early innate immune response against Listeria monocytogenes. J Exp Med 2006;203:933-940.
148. Dai WJ, Kohler G, Brombacher F. Both innate and acquired immunity to Listeria monocytogenes infection are increased in IL-10-deficient mice. J Immunol 1997;158:2259-2267.
149. Rayamajhi M, Humann J, Penheiter K, Andreasen K, Lenz LL. Induction of IFN-alphabeta enables Listeria monocytogenes to suppress macrophage activation by IFN-gamma. J Exp Med 2010;207:327-337.
150. Henry T, et al. Type I IFN signaling constrains IL-17A/F secretion by gammadelta T cells during bacterial infections. J Immunol 2010;184:3755-3767.
151. Iwakura Y, Nakae S, Saijo S, Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008;226:57-79.
152. Archer KA, Durack J, Portnoy DA. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog 2014;10:e1003861.
153. Wollert T, et al. Extending the host range of Listeria monocytogenes by rational protein design. Cell 2007;129:891-902.
154. Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med 2007;204:987-994.
155. Sauer JD, Witte CE, Zemansky J, Hanson B, Lauer P, Portnoy DA. Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe 2010;7:412-419.
156. Jones JW, et al. Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci USA 2010;107:9771-9776.
157. Jia T, Leiner I, Dorothee G, Brandl K, Pamer EG. MyD88 and Type I interferon receptor-mediated chemokine induction and monocyte recruitment during Listeria monocytogenes infection. J Immunol 2009;183:1271-1278.
158. Lindgren SW, Stojiljkovic I, Heffron F. Macrophage killing is an essential virulence mechanism of Salmonella typhimurium. Proc Natl Acad Sci USA 1996;93:4197-4201.
159. Farache J, et al. Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation. Immunity 2013;38:581-595.
160. Uematsu S, et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 2006;7:868-874.
161. Arpaia N, et al. TLR signaling is required for Salmonella typhimurium virulence. Cell 2011;144:675-688.
162. Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med 2010;207:1745-1755.
163. Franchi L, et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat Immunol 2006;7:576-582.
164. Miao EA, et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol 2006;7:569-575.
165. Raupach B, Peuschel SK, Monack DM, Zychlinsky A. Caspase-1-mediated activation of interleukin-1beta (IL-1beta) and IL-18 contributes to innate immune defenses against Salmonella enterica serovar Typhimurium infection. Infect Immun 2006;74:4922-4926.
166. Broz P, et al. Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature 2012;490:288-291.
167. Lara-Tejero M, et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J Exp Med 2006;203:1407-1412.
168. Freudenberg MA, Merlin T, Kalis C, Chvatchko Y, Stubig H, Galanos C. Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by Type I IFN and IL-18 signaling. J Immunol 2002;169:1665-1668.
169. Robinson N, et al. interferon induces necroptosis in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat Immunol 2012;13:954-962.
170. Chang EY, Guo B, Doyle SE, Cheng G. Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J Immunol 2007;178:6705-6709.
171. Fitzgerald DC, et al. Independent and interdependent immunoregulatory effects of IL-27, IFN-beta, and IL-10 in the suppression of human Th17 cells and murine experimental autoimmune encephalomyelitis. J Immunol 2013;190:3225-3234.
172. Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D. The production of IL-1 receptor antagonist in IFN-beta-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol 2005;174:2974-2980.
173. Dalod M, et al. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. J Exp Med 2002;195:517-528.
174. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007;131:1124-1136.
175. Shinohara ML, Kim JH, Garcia VA, Cantor H. Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008;29:68-78.
176. Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009;183:5418-5427.
177. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008;118:1680-1690.
178. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. J Exp Med 2011;208:2367-2374.
179. Teijaro JR, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013;340:207-211.
180. Wilson EB, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013;340:202-207.
181. Muller U, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994;264:1918-1921.
182. Tishon A, Lewicki H, Rall G, Von Herrath M, Oldstone MB. An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology 1995;212:244-250.
183. Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol 1985;135:1857-1863.
184. Yoshida R, Murray HW, Nathan CF. Agonist and antagonist effects of interferon alpha and beta on activation of human macrophages. Two classes of interferon gamma receptors and blockade of the high-affinity sites by interferon alpha or beta. J Exp Med 1988;167:1171-1185.
185. Richter K, et al. Macrophage and T cell produced IL-10 promotes viral chronicity. PLoS Pathog 2013;9:e1003735.
186. Fraietta JA, et al. Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection. PLoS Pathog 2013;9:e1003658.
187. Kulpa DA, Lawani M, Cooper A, Peretz Y, Ahlers J, Sekaly RP. PD-1 coinhibitory signals: the link between pathogenesis and protection. Semin Immunol 2013;25:219-227.
188. McNab FW, et al. TPL-2-ERK1/2 signaling promotes host resistance against intracellular bacterial infection by negative regulation of type I IFN production. J Immunol 2013;191:1732-1743.
189. Redford PS, et al. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J Infect Dis 2014;209:270-274.
190. Teles RM, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013;339:1448-1453.
191. Berry MP, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010;466:973-977.
192. McNab FW, et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol 2011;41:1941-1947.
193. Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe 2011;10:311-323.
194. Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012;30:759-795.
195. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002;13:111-118.
196. Lienenklaus S, et al. Novel reporter mouse reveals constitutive and inflammatory expression of IFN-beta in vivo. J Immunol 2009;183:3229-3236.
197. Munakata K, et al. Importance of the interferon-alpha system in murine large intestine indicated by microarray analysis of commensal bacteria-induced immunological changes. BMC Genom 2008;9:192.
198. Chirdo FG, Millington OR, Beacock-Sharp H, Mowat AM. Immunomodulatory dendritic cells in intestinal lamina propria. Eur J Immunol 2005;35:1831-1840.
199. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007;26:503-517.
200. Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 2001;167:1179-1187.
201. Yamamoto M, et al. A microarray analysis of gnotobiotic mice indicating that microbial exposure during the neonatal period plays an essential role in immune system development. BMC Genom 2012;13:335.
202. Kawashima T, et al. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-beta. Immunity 2013;38:1187-1197.
203. Rachmilewitz D, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 2002;122:1428-1441.
204. Rachmilewitz D, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528.
205. Rachmilewitz D, Karmeli F, Shteingart S, Lee J, Takabayashi K, Raz E. Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis. Inflamm Bowel Dis 2006;12:339-345.
206. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J Clin Invest 2005;115:695-702.
207. Abe K, et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci USA 2007;104:17022-17027.
208. McFarland AP, et al. Localized delivery of interferon-beta by Lactobacillus exacerbates experimental colitis. PLoS ONE 2011;6:e16967.
209. Sainathan SK, et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis 2008;14:88-99.
210. Sainathan SK, et al. Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. Inflamm Bowel Dis 2012;18:955-967.
211. Vijay-Kumar M, et al. Activation of toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm Bowel Dis 2007;13:856-864.
212. Hofmann C, et al. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Gut 2010;59:1347-1354.
213. Bleich A, et al. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. Gastroenterology 2009;136:278-287.
214. Bilsborough J, George TC, Norment A, Viney JL. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology 2003;108:481-492.
215. Moseman EA, et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004;173:4433-4442.
216. Radulovic K, et al. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential. J Immunol 2012;188:2001-2013.
217. Lee SE, et al. Type I interferons maintain Foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice. Gastroenterology 2012;143:145-154.
218. Hall JA, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity 2008;29:637-649.
219. Bouladoux N, et al. Regulatory role of suppressive motifs from commensal DNA. Mucosal Immunol 2012;5:623-634.
220. Lee J, Rachmilewitz D, Raz E. Homeostatic effects of TLR9 signaling in experimental colitis. Ann N Y Acad Sci 2006;1072:351-355.
221. Lee J, et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006;8:1327-1336.
222. Mirpuri J, et al. Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine. J Immunol 2010;184:7186-7195.
223. Tschurtschenthaler M, et al. Type I interferon signalling in the intestinal epithelium affects Paneth cells, microbial ecology and epithelial regeneration. Gut 2014; doi: 10.1136/gutjnl-2013-305863. [Epub ahead of print].
224. Tezuka H, et al. Prominent role for plasmacytoid dendritic cells in mucosal T cell-independent IgA induction. Immunity 2011;34:247-257.
225. Litinskiy MB, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002;3:822-829.
226. Ichinohe T, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 2011;108:5354-5359.
227. Abt MC, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. Immunity 2012;37:158-170.
228. Ganal SC, et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012;37:171-186.
229. Franke A, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
230. Anderson CA, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-252.
231. Rivas MA, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011;43:1066-1073.
232. Jostins L, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
233. Beaudoin M, et al. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS Genet 2013;9:e1003723.
234. Brant SR. Promises, delivery, and challenges of inflammatory bowel disease risk gene discovery. Clin Gastroenterol Hepatol 2013;11:22-26.
235. Wang Y, et al. The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. Immunity 2013;39:111-122.
236. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704-1712.
237. Musch E, Andus T, Malek M, Chrissafidou A, Schulz M. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta-an open long-term trial. Z Gastroenterol 2007;45:1235-1240.
238. Madsen SM, et al. An open-labeled, randomized study comparing systemic interferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am J Gastroenterol 2001;96:1807-1815.
239. Nikolaus S, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 2003;52:1286-1290.
240. Mannon PJ, et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 2011;60:449-455.
241. Kaser A, Molnar C, Tilg H. Differential regulation of interleukin 4 and interleukin 13 production by interferon alpha. Cytokine 1998;10:75-81.
242. Gasche C, et al. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995;40:800-804.
243. Pena Rossi C, Hanauer SB, Tomasevic R, Hunter JO, Shafran I, Graffner H. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol 2009;9:22.
244. Pena-Rossi C, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-767.
245. Musch E, et al. Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2005;3:581-586.
246. Monteleone G, Pender SL, Wathen NC, MacDonald TT. Interferon-alpha drives T cell-mediated immunopathology in the intestine. Eur J Immunol 2001;31:2247-2255.
247. Di Sabatino A, et al. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 2007;133:1175-1187.
248. Stewart CA, et al. Interferon-dependent IL-10 production by Tregs limits tumor Th17inflammation. J Clin Invest 2013;123:4859-4874.
249. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010;30:555-564.
250. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunol Rev 2013;255:25-39.
251. Monteleone G, et al. Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 2001;48:425-429.